NCT05280054View on ClinicalTrials.gov

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

November 1, 2022

Conditions

Drug Drug Interaction

Interventions

DRUG

AV-101

360 mg capsules

DRUG

Probenecid

1000 mg oral

Trial Locations (1)

91206

RECRUITING

Parexel Early Phase Clinical Unit, Glendale

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

VistaGen Therapeutics, Inc.

INDUSTRY